HSBC recently initiated coverage of CVS Health (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA) in a client note on Friday.

For CVS Health, HSBC assigned a Buy rating with a price target of $94 per share. The bank views CVS as having an attractive and undervalued competitive advantage and noted that it is trading at a significant discount compared to its historical levels. Additionally, HSBC pointed out that CVS’s shares have declined about 18% over the last twelve months (LTM), in contrast to the S&P 500 Index, which has risen by 23% during the same period. This discrepancy leads HSBC to believe that the sell-off in CVS’s stock might be excessively severe.

On the other hand, Walgreens Boots Alliance was given a Hold rating with a price target of $27 per share. HSBC acknowledged that WBA requires enhanced operational discipline to improve its execution and overall performance, with a particular focus on restoring profitability. Despite facing near-term operational challenges, HSBC sees potential for WBA to unlock value. However, the analysts cautioned that the risks associated with execution are significant.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

× ¿Cómo puedo ayudarte?